Amgen reported fourth-quarter 2025 revenues and adjusted EPS above consensus, driven by a 7% year-over-year increase in product sales and a lower effective tax rate. The company’s GAAP net income of $1.33 billion marked a notable improvement over the prior year, while operational leverage from cost controls contributed to margin expansion. Full-year 2026 guidance was raised above Street estimates, reflecting management’s confidence in balancing growth investments with disciplined spending.

Despite major loss-of-exclusivity (LOE) events on flagship products Prolia, Xgeva and Ravicti, Amgen expects newly growing franchises—Repatha (PCSK9 inhibitor), Uplizna (neuromyelitis optica), Evenity (osteoporosis), Imdelltra (iron therapy) and Tezspire (severe asthma)—to collectively offset LOE revenue declines. Repatha’s recent trial data demonstrated a 23% incremental LDL-cholesterol reduction versus statin alone, underpinning forecasted double-digit sales growth for that franchise in 2026.

Regulatory uncertainty around Tavneos (avacopan) poses upside risks, as the FDA’s forthcoming review could influence international rollout timing. Meanwhile, recent setbacks in oncology mid-stage assets rocatinlimab and bemarituzumab highlight pipeline attrition challenges. Offsetting these concerns, positive Phase II data for Amgen’s MariTide anticancer program and advancing filing plans for sotorasib in KRAS-mutant tumors support the long-term investment thesis.